These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 21699444)

  • 1. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
    Kim M; Thompson LA; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romidepsin for the treatment of non-Hodgkin's lymphoma.
    Yazbeck VY; Grant S
    Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
    Jain N; Odenike O
    Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery and development of romidepsin for the treatment of T-cell lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2017 Aug; 12(8):859-873. PubMed ID: 28641053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
    Grant C; Rahman F; Piekarz R; Peer C; Frye R; Robey RW; Gardner ER; Figg WD; Bates SE
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):997-1008. PubMed ID: 20645688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romidepsin for cutaneous T-cell lymphoma.
    Prince HM; Dickinson M
    Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Romidepsin (Istodax
    Ro T; Nakayama N; Achiwa H; Ohtsu T
    Nihon Yakurigaku Zasshi; 2018; 151(3):122-129. PubMed ID: 29526921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
    Rangwala S; Zhang C; Duvic M
    Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin for the treatment of cutaneous T-cell lymphoma.
    Campas-Moya C
    Drugs Today (Barc); 2009 Nov; 45(11):787-95. PubMed ID: 20126671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
    Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
    Thaler F
    Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romidepsin for the treatment of T-cell lymphomas.
    McGraw AL
    Am J Health Syst Pharm; 2013 Jul; 70(13):1115-22. PubMed ID: 23784158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
    Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romidepsin: in the treatment of T-cell lymphoma.
    Yang LP
    Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belinostat: clinical applications in solid tumors and lymphoma.
    Molife LR; de Bono JS
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.